Abstract:Amorphous solid dispersions (ASDs) of class II and IV biopharmaceutics classification system drugs in water-miscible polymers are a well-recognized means of enhancing dissolution, while such dispersions in hydrophobic polymers form the basis of micro- and nanoparticulate technologies. However, drug recrystallization presents significant problems for product development, and the mechanisms and pathways involved are poorly understood. Here, we outline the use of combined differential scanning calorimetry (DSC)-synchrotron X-ray diffraction to monitor the sequential appearance of polymorphs of olanzapine (OLZ) when dispersed in a range of polymers. In a recent study (Cryst. Growth Des.2019,19, 2751-2757), we reported a new polymorph (form IV) of OLZ which crystallized from a spray-dried dispersion of OLZ in polyvinylpyrrolidone. Here, we extend our earlier study to explore OLZ dispersions in poly(lactide-co-glycolide) (PLGA), polylactide (PLA), and hydroxypropyl methyl cellulose acetate succinate (HPMCAS), with a view to identifying the sequence of form generation on heating each dispersion. While spray-dried OLZ results in the formation of crystalline form I, the spray-dried material with HPMCAS comprises an ASD, and forms I and IV are generated upon heating. PLGA and PLA result in a product which contains both amorphous OLZ and the dichloromethane solvate; upon heating, the amorphous material converts to forms I, II, and IV and the solvate to forms I and II. Our data show that it is possible to quantitatively assess not only the polymorph generation sequence but also the relative proportions as a function of temperature. Of particular note is that the sequence of form generation is significantly more complex than may be indicated by DSC data alone, with coincident generation of different polymorphs and complex interconversions as the material is heated. We argue that this may have implications not only for the mechanistic understanding of polymorph generation but also as an aid to identifying the range of polymorphic forms that may be produced by a single-drug molecule.

Stability and Phase Transition Investigation of Olanzapine Polymorphs

Rational Crystal Polymorph Design of Olanzapine

Crystal Morphology Prediction of Olanzapine Forms III and IV

A Simultaneous Differential Scanning Calorimetry-X-ray Diffraction Study of Olanzapine Crystallization from Amorphous Solid Dispersions

Crystal structure determination of the antipsychotic drug of olanzapine form III.

Polymorphs and pharmacokinetics of an antipsychotic drug candidate

A Solid-Solid Phase Transformation of Triclabendazole at High Pressures

Prediction of the physical stability of amorphous solid dispersions: relationship of aging and phase separation with the thermodynamic and kinetic models along with characterization techniques

Thermodynamic and Kinetic Investigation of Agomelatine Polymorph Transformation.

A New Polymorphic Form of Metoprolol Succinate

Polymorphism of Pradofloxacin: Crystal Structure Analysis, Stability Study, and Phase Transformation Behavior

Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate

Thermodynamic and kinetic mechanism of phase transformation of levofloxacin hydrochloride

Modeling Olanzapine Solution Growth Morphologies

An Enantiotropic Disorder–Partial Order Solid-State Transformation in a Molecular Solid Involving a Phase with Z′ = 12

Water-mediated phase transformations of posaconazole: An intricate jungle of crystal forms

The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine

Characterizing the carbamazepine polymorphs , solubility and metastable zone measurement

Crystal Structure Optimization and Gibbs Free Energy Comparison of Five Sulfathiazole Polymorphs by the Embedded Fragment QM Method at the DFT Level

Study on the Polymorphism of Agomelatine

Formation of a metastable phase induced by a liquid crystalline phase in a novel chloropoly(aryl ether ketone)